Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time 2024-03-18 20:32
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022 2023-07-31 18:02
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022 2023-04-24 18:03
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index 2022-12-21 08:00
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan 2022-11-30 08:00
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion 2022-10-26 19:06
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility 2022-09-26 20:00
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers 2022-09-09 20:00
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware 2022-08-17 01:47
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology 2022-08-12 09:09
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation 2022-07-19 17:59
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility 2022-07-07 08:00
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies 2022-06-16 08:00
WuXi AppTec Reports Record First-Quarter In 2022 2022-04-25 17:52
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies 2022-03-08 08:00
1